Table 2.
Univariate Analysis Evaluating Potential Predictors for Mortality in the 278 Patients with Clinically Localized Prostate Cancer who Underwent Open RRP
| Variables | No. | Overall mortality
|
Disease-specific mortality
|
Recurrence
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | ||
| Age* | 278 | 1.01 | (0.967; 1.05) | 0.74 | 0.98 | (0.934; 1.02) | 0.31 | 1.03 | (1.01; 1.05) | 0.01 |
| Pathological tumor stage | 278 | 3.48 | (2.28; 5.3) | <0.001 | 4.52 | (2.75; 7.4) | <0.001 | 1.96 | (1.51; 2.55) | <0.001 |
| Pathological lymph node status | 261 | 3.58 | (2.17; 5.91) | <0.001 | 5.48 | (2.96; 10.2) | <0.001 | 2.42 | (1.77; 3.32) | <0.001 |
| Tumor grade | 263 | 2.63 | (1.71; 4.05) | <0.001 | 3.21 | (1.92; 5.36) | <0.001 | 1.75 | (1.37; 2.23) | <0.001 |
| Gleason score† | 276 | 2.77 | (1.88; 4.08) | <0.001 | 3.3 | (2.09; 5.23) | <0.001 | 1.66 | (1.34; 2.06) | <0.001 |
| MMP-2% | 278 | 1.05 | (0.871; 1.26) | 0.63 | 1.08 | (0.87; 1.35) | 0.47 | 1.08 | (0.968; 1.20) | 0.17 |
| MMP-2 intensity | 278 | 1.03 | (0.796; 1.32) | 0.84 | 0.947 | (0.703; 1.27) | 0.72 | 1.03 | (0.89; 1.20) | 0.69 |
| MMP-3% | 278 | 0.917 | (0.725; 1.16) | 0.47 | 0.858 | (0.637; 1.16) | 0.31 | 0.953 | (0.836; 1.09) | 0.47 |
| MMP-3 intensity | 278 | 0.891 | (0.588; 1.35) | 0.59 | 0.756 | (0.43; 1.33) | 0.33 | 0.995 | (0.79; 1.25) | 0.96 |
| MMP-7% | 278 | 0.893 | (0.773; 1.03) | 0.13 | 0.87 | (0.738; 1.03) | 0.1 | 0.933 | (0.85; 1.02) | 0.15 |
| MMP-7 intensity | 278 | 1.01 | (0.695; 1.46) | 0.97 | 1.08 | (0.704; 1.64) | 0.73 | 0.993 | (0.775; 1.27) | 0.96 |
| MMP-9% | 278 | 0.832 | (0.693; 0.99) | 0.048 | 0.813 | (0.661; 0.999) | 0.049 | 0.875 | (0.775; 0.99) | 0.03 |
| MMP-9 intensity | 278 | 0.602 | (0.452; 0.8) | <0.001 | 0.511 | (0.359; 0.727) | <0.001 | 0.874 | (0.746; 1.02) | 0.096 |
| MMP-13% | 278 | 0.922 | (0.735; 1.16) | 0.48 | 0.925 | (0.71; 1.21) | 0.56 | 0.948 | (0.821;1.10) | 0.47 |
| MMP-13 intensity | 278 | 0.814 | (0.55; 1.21) | 0.31 | 0.765 | (0.481; 1.22) | 0.26 | 0.833 | (0.663; 1.05) | 0.12 |
| MMP-19% | 278 | 0.997 | (0.868; 0.15) | 0.97 | 0.983 | (0.835; 1.16) | 0.84 | 0.948 | (0.87; 1.03) | 0.22 |
| MMP-19 intensity | 278 | 0.727 | (0.476; 1.11) | 0.14 | 0.794 | (0.486; 1.30) | 0.36 | 0.83 | (0.649; 1.06) | 0.14 |
| CD 31 count | 278 | 1.19 | (0.965; 1.47) | 0.1 | 1.24 | (0.97; 1.58) | 0.088 | 1.03 | (0.903; 1.17) | 0.69 |
| VEGF % | 278 | 1.11 | (0.934; 1.33) | 0.23 | 1.05 | (0.864; 1.28) | 0.61 | 1.05 | (0.944; 1.16) | 0.38 |
| VEGF intensity | 278 | 1.24 | (0.954; 1.61) | 0.11 | 1.09 | (0.794; 1.49) | 0.6 | 1.08 | (0.917; 1.27) | 0.36 |
| BFGF tumor | 278 | 0.952 | (0.679; 1.34) | 0.78 | 0.918 | (0.614; 1.37) | 0.67 | 0.93 | (0.755; 1.15) | 0.5 |
| BFGF stroma | 278 | 0.952 | (0.673; 1.35) | 0.78 | 1.24 | (0.851; 1.81) | 0.26 | 1.01 | (0.816; 1.25) | 0.93 |
| HIF 1α % | 278 | 0.992 | (0.84; 1.17) | 0.92 | 1.01 | (0.828; 1.22) | 0.95 | 1.04 | (0.942; 1.15) | 0.42 |
| HIF 1α intensity | 278 | 1.01 | (0.72; 1.46) | 0.95 | 1.07 | (0.699; 1.63) | 0.77 | 1.11 | (0.886; 1.39) | 0.37 |
HR: hazard ratio.
95% CI: confidence interval.
*
Age: per additional year.
†
Gleason score: low- (2 to 4), intermediate- (5 to 7), high- (8 to 10) risk disease.
Bold indicates P < 0.05, significant.